Independent validation of progression-free survival rate at 9 and 18 weeks (PFSR-18, PFSR-9) as predictor for overall survival (OS) in patients with malignant pleural mesothelioma (MPM): EORTC 08052 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback